Pregnancy outcomes in patients exposed to interferon beta-1b: Table 1
نویسندگان
چکیده
منابع مشابه
Pregnancy outcomes in patients exposed to interferon beta-1b
withstand the 20 min rotation, some were not completely immune, perhaps because of residual vestibular function. Some degree of otolith function could still be present since caloric and rotational tests primarily assess horizontal semicircular canal function. It is also known that visual stimuli can provoke symptoms, and since the experiment took place in the light, this may be an alternative e...
متن کاملPregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
BACKGROUND Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment. METHODS We examined individual patient data from eight clinical trials with IFNbeta-1a. RESULTS Of 3,361 women in the studies, 69 pregnancies were reported, of which 41 were patients receiving (or who had s...
متن کاملPregnancy outcomes of women exposed to laninamivir during pregnancy
PURPOSE The purpose of this study is to assess pregnancy outcomes of women treated with a novel neuraminidase inhibitor, laninamivir, during pregnancy. METHODS A retrospective review of pregnancy outcomes of 112 pregnant women who were given laninamivir for treatment of influenza was performed. Possible adverse events, including miscarriages, preterm birth, foetal malformation and any neonata...
متن کاملResponse to beta interferon 1b among Saudi patients with multiple sclerosis.
OBJECTIVE To determine the efficacy and tolerability of subcutaneous beta interferon 1b (B1F1b) among Saudi patients with remitting-relapsing multiple sclerosis (R-R MS). METHODS An open label study held at the Neurology Division of the Armed Forces Hospital, Riyadh from March 1997 until December 2001. Thirty-two consecutive patients below the age of 50 years with clinically definite R-R MS a...
متن کاملApplication of Interferon Beta-1b in Multiple Sclerosis
Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 2014
ISSN: 0022-3050,1468-330X
DOI: 10.1136/jnnp-2014-308113